Bellerophon Therapeutics (BLPH) Tops Q1 EPS by 75c

Bellerophon Therapeutics (NASDAQ: BLPH) reported Q1 EPS of $0.27, $0.75 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $5.64 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Bellerophon Therapeutics (BLPH) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Dell’s earning report was bullish for Intel CPU demand, analyst says
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight